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ABSTRACT 
Metronomic chemotherapy refers to the chronic, equally spaced, delivery of low doses of 
chemotherapeutic drugs, without extended interruptions. Previously, we developed two 
combined metronomic schemes for the treatment of murine mammary tumors. The aim of 
this study was to compare their effects on tumor and metastasis growth, survival and 
toxicity. Metronomic chemotherapy with Cyclophosphamide + Celecoxib showed higher 
antimetastatic power than Cyclophosphamide + Doxorubicin, while being similar in other 
aspects. That difference, plus the advantage that represents its oral administration, points at 
the election of Cyclophosphamide + Celecoxib combination for the metronomic treatment 
of mammary tumors. 
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INTRODUCTION 
Metastatic breast cancer, as most of advanced tumors, remains incurable, and its treatment 
is limited to palliative management, with the objective to prolong progression free survival, 
overall survival and provide an acceptable quality of life. The problem of metastatic breast 
cancer management persists, in spite of having a good response, at least in local stages and 
despite the inclusion of new targeted agents which usually have a modest impact in 
therapeutic efficacy (1, 2).   
The concept of metronomic chemotherapy (MCT) is well known in the oncology research 
area. Briefly, it refers to the chronic administration of low doses of chemotherapeutic drugs, 
at frequent and regular intervals, without extended rest periods, allowing a continuous and 
chronic treatment for different kinds of tumors, without side effects or severe toxicity (3). 
Prolonged rest periods, needed after a standard chemotherapy for the recovery of patients 
from common toxicities, represent an opportunity for specific and resistant cancer cells to 
re-grow. Those facts underline the importance of avoiding or reducing rest periods.  .   
Several mechanisms of action like inhibition of angiogenesis, restoration of anti-tumor  
immune response and induction of tumor dormancy, has been proposed to explain MCT 
therapeutic effect (4, 5).  
Cox-2 plays an important role in carcinogenesis and tumor growth and progression (6-9).  
This enzyme is frequently expressed in invasive and in situ breast cancers (10, 11).  The use 
of Cox-2 inhibitors in cancer therapy has proved to be effective, inhibiting cell proliferation 
and angiogenesis. 
In the same way, Cyclophosphamide, an alkylating agent that has been used for decades 
and it is presently used in standard chemotherapy, is one of the first and most studied drugs 
in metronomic or low dose administration settings. Its antiangiogenic and 
immunomodulating effects were probed in different experimental tumor-models and also in 
the clinic (3). 
Doxorubicin is an anthracycline widely used in cancer chemotherapy, commonly utilized 
for treating several types of cancers. Different authors found that the metronomic 
administration of this drug, alone or in combination with Cy, brings about an antitumor an 
antimetastatic effect (5, 12, 13). 
Considering the high incidence of mammary tumors in humans, we had studied the 
therapeutic efficacy and the mechanism/s of action of MCT with cyclophosphamide (Cy) as 
a single drug and combined with Celecoxib (Cel) (14), or with doxorubicin (Dox) (5), in 
two mouse mammary adenocarcinomas (MA) tumor-models. 
The aim of the present work was to compare the results previously obtained on efficacy and 
toxicity in animals bearing two different MA, treated with two different MCT regimens: 
Cy+Cel or Cy+Dox. 
MATERIALS AND METHODS 
Animals.  
Inbred BALB/c and CBi female mice were obtained from our breeding facilities. Animals 
were fed with commercial chow and water ad libitum and maintained in a 12-h light/dark 
cycle. All the experiments were developed during the first half of the light cycle. Tumor-
bearing mice were euthanized by CO2 exposure. The animals were treated in accordance to 
the Canadian Council on Animal Care guidelines (15).   
Drugs.  
Cyclophosphamide (Laboratorio Filaxis, SA, Argentina) was dissolved in sterile distilled 
water at a concentration of 20 mg/ml and diluted in the drinking water to reach 0.12 mg/ml. 
Drinking water was replaced every other day and the mice’s daily Cy intake/kg body 
weight (BW) was calculated. 
Doxorubicin (Laboratorio Filaxis, SA, Argentina) was dissolved in sterile saline 
immediately before its intraperitoneal injection. 
Celecoxib (Pfizer Corp, Chicago, USA) was dissolved in dimethylsulfoxide at a 
concentration of 200 mg/ml. Immediately before its administration by gavage, it was 
further diluted with phosphate buffer saline to a concentration of 2 mg/ml (8). 
Tumors 
The mouse mammary tumors M-234p and M-406, established in our laboratory, were used.  
M-234p: Is a type B (16)  moderately differentiated mammary adenocarcinoma that shows 
a mixed pattern and develops lung metastasis. It spontaneously arose in a BALB/c female 
mouse, and it is maintained in vivo by serial subcutaneous passages in syngeneic mice, with 
100% of incidence. 
M-406: Is a type B semi-differentiated mammary adenocarcinoma which appeared 
spontaneously in an inbred CBi female mouse. It is maintained in vivo by serial 
intraperitoneal passages in syngeneic mice, with 100% of incidence. 
Treatments 
A) MCT Cy+Cel: Adult BALB/c or CBi female mice were implanted subcutaneously in 
their right flanks with ≅1-mm3 M-234p (I) or M-406 (II) tumor fragments, respectively. 
Five (for M-234p) or eight (for M-406) days later, when the tumors reached ≅150 mm3, 
the animals were distributed in four groups. (N=6-7 and N=5-6/group for M-234p and 
M-406, respectively) and treated as follows: Control: regular drinking water without 
drug administration; Cy: In drinking water (≅30 mg/kg BW/day); Cel: Oral Cel (≅30 
mg/kg p.o.), five times/week; Cy+Cel: Treatments combined.  
B) MCT Cy+Dox: Adult BALB/c or CBi mice were implanted s.c. with ≅1 mm3 M-234p 
(I) or M-406 (II) tumor fragments, respectively. Five (M-234p) or eight (M-406) days 
later, when tumors reached ≅150 mm3, animals (N=5–8/group) were distributed and 
treated as follows: Control: regular drinking water without drug administration; Cy: in 
drinking water (≅30 mg/kg BW/day); Dox: 0.5 mg/kg/BW, i.p. three times/week; 
Cy+Dox: treatments combined. 
Antitumor and anti-metastatic effects. 
Antitumor effect. Tumor sizes were measured with Vernier calipers, and tumor volumes 
were calculated as follows: v = 0.4 (ab2), where v = volume (mm3), a = largest diameter 
(mm) and b = smallest diameter. Animals were weighed twice/week, and blood samples 
were obtained on day 0 and days 24 (M-234p) or 25 (M-406) for white blood cell count. 
When the first animal reached the largest ethically permitted tumor volume (LPV), animals 
belonging to the four groups were euthanized. For survival studies, in a duplicate 
experiment, animals were euthanized when each one reached LPV. 
Antimetastatic effect. Adult BALB/c and CBi mice were injected intravenously with 5 × 
105 M-234p cells and 2 × 105 M-406 cells in 0.1 ml saline, respectively. On day 3, animals 
were treated as indicated above (MCT Cy+Cel and MCT Cy+Dox). The animals were 
controlled daily and weighed twice/week. All the mice were euthanized by the time the first 
mouse showed signs of metastatic illness. Lungs were excised, weighed, and then fixed in 
Bouin’s solution to determine the number and size of metastatic foci. With both data the 
total metastatic burden/mouse was calculated.  
Treatment comparison.  
As we had previously demonstrated that the therapeutic efficacy of the combined treatment 
groups was significantly higher than that achieved with each individual drug, the data 
herein analyzed were those belonging to the groups of animals that received MCT with 
both drugs. For the efficacy comparison we calculated the percentages of reduction with 
respect to each control group of both, tumor and lung metastatic volumes of each group of 
combined treatment. In the same way, the percentages of survival increase with respect to 
controls were also determined and statistically compared.  
Statistical analysis 
Kruskal–Wallis and Dunn’s Multiple Comparison Test were used to examine the 
differences between groups with GraphPad Prism® version 3.0 (GraphPad Software, San 
Diego, CA). Differences were considered statistically significant at P < 0.05. 
RESULTS  
As previously informed, both treatments significantly inhibited tumor growth (5, 14). The 
% of reduction of tumor volume of animals in the combined treated group with respect to 
control group without treatment [median (range): AI: 84.4 % (30-99.4), AII: 77.9 % (50.9-
89.9), BI: 75.5 % (62.5-96.8), BII: 95.6 (57-99.6] did not differ between treatments or 
between tumor-models (Kruskal-Wallis non-parametric ANOVA) (Table 1). 
Mice that received MCT with Cy+Cel or Cy+Dox, showed a significantly higher survival 
than the corresponding control mice in both tumor models. When treatments were 
compared to each other, and interesting effect was observed, while in the M-234p tumor 
model the Cy + Cel treatment duplicates the survival with respect to the Cy + Dox 
treatment [AI: 77.6% (5.3–84.2); BI: 36.1% (12.4–113), respectively], on the other hand, in 
the M-406 tumor model occurred exactly the opposite  [AII: 56.5% (−4.3–56.5), BII: 
110.9% (60–308.2), respectively]. Because of those discrepancies, the statistical 
comparison did not reach significance, in spite of being close to it (P=0.054) (Table 2).  
The lung metastatic burden was found to be diminished in both therapeutic schemes. The % 
of reduction of lung metastatic volume [AI: 99.7 % (98.7-100), AII: 99.8 % (97.1-99.2), BI: 
90 % (48.4-99.3), BII: 90.6 % (35.9-96.6)] was significantly different among all the groups 
(P<0.01); Dunn’s post-test showed differences in AIvs BI (P<0.05). (Table 3) 
The surrogate markers of morbidity/toxicity monitored, namely the motor activity, fur 
quality, food intake, response to stimuli and breathing, plus the evolution of body weight 
and total leucocytes count showed no differences with respect to their respective controls, 
along the experiments, independently of the tumor-models or treatments (Data not shown). 
 
DISCUSSION 
The combination of two or more existing chemotherapy agents in order to achieve 
therapeutic synergism is an interesting goal in most of the metronomic schedules assayed.  
A number of authors have studied the therapeutic effect of metronomic chemotherapy in 
either the pre-clinical or the clinical field, using different drug combinations. Just to 
mention a few, Cy combined with other agents like anti-VEGFR antibody (17), TNP-470 
(18), imatinib (19), peptide ABT-510 (20), tirapazamine (21), cetixumab (22), 5-
fluorouracil pro-drug UFT (23), axitinib (24), gemcitabine (25) and celecoxib (26-28). 
Some of them were developed in tumor-models of mammary adenocarcinomas (18, 21-23, 
26). The therapeutic results achieved with the different drugs combinations were variable. 
Also, those therapeutic schedules were accompanied by the presence or absence of toxic 
effects. Hence, it is somewhat difficult to identify which is, for a determined type of tumor, 
the best metronomic drug combination in terms of efficacy and derived toxicity, two 
properties that in turn, will determine the extension and the quality of life of the tumor 
bearers. 
Following this line of thought we decided to compare the antitumor and the antimetastatic 
efficacy of the two drug combinations tested in our lab to treat two murine mammary 
adenocarcinomas. 
The antitumor efficacy and the increase in survival did not show statistical differences, 
either among treatments or tumor-models. On the other hand, the combination of Cy+Cel 
was superior than Cy+Dox related to antimetastatic power, suggesting its potential use at 
the adjuvant setting. 
In matter of toxicity, both treatments showed low to null toxic effects. No weight losses 
were detected throughout the experiment in any of the groups of both tumor models. Also, 
no alterations were found in the markers of morbidity/toxicity monitored (5, 14).  
Therefore, the quality of life in both combinations would be similar. Nevertheless, if we 
take into consideration that the administration of Cy+Cel is exclusively oral, while the 
Cy+Dox schedule has the drawback of the Dox intraperitoneal injection, the scale tilts into 
the Cy+Cel direction.  
The statistical comparison we made allows us to choose the Cy+Cel treatment as the best of 
our MCT treatments. But, what about the different schedules and combinations tested by 
other researchers in other models? Are them better, similar o worse, in efficacy and 
toxicity, than that achieved with our treatment? Which one would be the better choice to 
translate to the clinic? Speaking particularly about mammary adenocarcinoma treatment, it 
would be of interest that other authors calculate their own percentages of decrease in tumor 
and metastasis volume and the percentages of survival increase with respect to controls. 
The availability of such data would enable to compare different schedules and 
combinations of MCT for mammary tumors for their translation to the clinic. 
In the meantime, in the clinical field,  metronomic Cy+Cel schedule for treating advanced 
breast cancer patients is being tested, showing a good response and low to null toxicity 
(26). 
In conclusion, although both combined metronomic treatments were fairly similar respect 
to the absence of toxicity and to the inhibition of tumor growth, leading to an increased 
survival, the election of the Cy+Cel combination as the better one, was based in its 
antimetastatic power and also because of the advantage that represents its oral 
administration. The last one is not a minor advantage, since the development of these oral 
chemotherapies allows an effective treatment with an easy drug administration, with less 
significant adverse effects, providing better outpatient management without the emotional 
burden that intravenous chemotherapy represents.  
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Table 1. Percentage of reduction of tumor volume with respect to control group. ANOVA (Kruskal-
Wallis): N.S. 
 
 
 
 
 
 
 
TUMOR 
PERCENTAGE OF TUMOR VOLUME REDUCTION                             
(median-range) 
A. Cy + Cel B. Cy + Dox 
I. M-234p 84,4 % (30-99.4) 75.5 % (62.5-96.8) 
II. M-406 77.9 % (50,9-89,9) 95.6 % (57-99.6) 
  
Table 2. Percentage of survival increase with respect to control group. ANOVA (Kruskal-Wallis): 
P=0.054  
 
 
 
 
TUMOR 
PERCENTAGE OF SURVIVAL INCREASE                                                     
(median-range) 
A. Cy + Cel B. Cy + Dox 
 I. M-234p 77.6 % (5.3-84,2) 36.1 % (12.4-113) 
II. M-406 56.5 % (-4.3-56,5) 110.9 % (60-308.2) 
  
Table 3. Percentage of reduction of lung metastatic burden with respect to control group.  ANOVA 
(Kruskal-Wallis):  P<0.01; I. M-234p: Cy+Cel vs Cy+ Dox, P<0.05 (Dunn’s Multiple Comparison Test)  
 
 
TUMOR 
PERCENTAGE OF LUNG METASTATIC BURDEN REDUCTION 
(median-range) 
A. Cy + Cel B. Cy + Dox 
  I. M-234p 99.7 % (98.7-100) 90 % (48.4-99.3) 
II. M-406 99.8 % (97.1-99.2) 90,6 % (35.9-96.6) 
